This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Sarclisa

Prescribing Information for SARCLISA® (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

Dr Ceri Bygrave talks through how to translate IMROZ into clinic, including IsaVRd dosing, good prophylaxis measures, considerations for tailoring treatments, and supportive medications.

Overview of SARCLISA®


Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Overview of SARCLISA®


Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Get in touch with the Oncology Team

RRMM and Ti NDMM

Sarclisa logo

RRMM

Learn more  →

Prescribing information UK

MAT-XU-2502442 (v1.0)
Date of preparation: August 2025  

Sarclisa logo

Ti NDMM

Learn more  →

Prescribing information UK

MAT-XU-2202578 (v7.0)
Date of preparation: August 2025  

MAT-XU-2503137 (v1.0) Date of Preparation: August 2025